Establishment of an Experimental System for Intraperitoneal Chemotherapy in a Rat Model

Overview

Journal In Vivo

Specialty Oncology

Date 2021 Aug 19

PMID 34410959

Citations 2

Authors

Sunwoo Park

Soo Jin Park

Hee Su Lee

Jiyeon Ham

Eun Ji Lee

JunSik Kim

Soomin Ryu

Aeran Seol

Whasun Lim

Jung Chan Lee

Gwonhwa Song

Hee Seung Kim

Affiliations

Soon will be listed here.

Abstract

Aim: To establish an experimental system for comparing different methods of intraperitoneal chemotherapy in a rat model.

Materials And Methods: We used six-week-old Sprague-Dawley rats, and created an early postoperative intraperitoneal chemotherapy (EPIC) system using 18-gauge syringes and evacuators, and a hyperthermic intraperitoneal chemotherapy (HIPEC) system using two peristaltic pumps which controlled the flow rate and temperature. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) was achieved using a nozzle for dispersing aerosols at a flow rate up to 41.5 ml/min. The distribution and intensity of 0.2% trypan blue dye was compared among three methods.

Results: The distribution was limited and the intensity was weak after EPIC, and the dye stained moderately in gravity-dependent regions after HIPEC. On the other hand, the distribution was the most comprehensive, and the intensity was the greatest after PIPAC.

Conclusion: This experimental system in a rat model may reflect the comparative effect among EPIC, HIPEC and PIPAC in humans.

Citing Articles

The results of designing a new prototype device and algorithm in closed method intraperitoneal hyperthermia model in rats.

Ulubay M, Sevinc E, Alp Goksel B, Ali Aksoy O Ulus Travma Acil Cerrahi Derg. 2023; 29(8):841-849.

PMID: 37563905 PMC: 10560800. DOI: 10.14744/tjtes.2023.27339.

Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework.

Baggaley A, Lafaurie G, Tate S, Boshier P, Case A, Prosser S Br J Surg. 2022; 110(1):10-18.

PMID: 36056893 PMC: 10364525. DOI: 10.1093/bjs/znac284.

References

Glehen O, Stuart O, Mohamed F, Sugarbaker P . Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. Cancer Chemother Pharmacol. 2004; 54(1):79-84. DOI: 10.1007/s00280-004-0779-0. View

Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X . Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. Eur J Surg Oncol. 2019; 45(3):301-309. DOI: 10.1016/j.ejso.2018.10.528. View

Aghayeva A, Benlice C, Bilgin I, Atukeren P, Dogusoy G, Demir F . The effects of hyperthermic intraperitoneal chemoperfusion on colonic anastomosis: an experimental study in a rat model. Tumori. 2017; 103(3):307-313. DOI: 10.5301/tj.5000610. View

Miailhe G, Arfi A, Mirshahi M, Eveno C, Pocard M, Touboul C . A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin. J Visc Surg. 2017; 155(3):183-189. DOI: 10.1016/j.jviscsurg.2017.10.008. View

Jung D, Son S, Oo A, Park Y, Shin D, Ahn S . Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model. Surg Endosc. 2015; 30(10):4258-64. DOI: 10.1007/s00464-015-4738-0. View

Tempfer C, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J . Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol Oncol. 2015; 137(2):223-8. DOI: 10.1016/j.ygyno.2015.02.009. View

Park S, Kim J, Kim S, Lee E, Oh S, Seol A . Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys. Jpn J Clin Oncol. 2018; 49(2):137-145. DOI: 10.1093/jjco/hyy175. View

Nair A, Jacob S . A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016; 7(2):27-31. PMC: 4804402. DOI: 10.4103/0976-0105.177703. View

Padilla-Valverde D, Sanchez-Garcia S, Garcia-Santos E, Marcote-Ibanez C, Molina-Robles M, Martin-Fernandez J . Usefulness of thermographic analysis to control temperature homogeneity in the development and implementation of a closed recirculating CO chemohyperthermia model. Int J Hyperthermia. 2016; 33(2):220-226. DOI: 10.1080/02656736.2016.1237679. View

10.

Pestieau S, Belliveau J, Griffin H, Stuart O, Sugarbaker P . Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol. 2001; 76(2):106-14. DOI: 10.1002/1096-9098(200102)76:2<106::aid-jso1020>3.0.co;2-e. View

11.

Bouquet W, Ceelen W, Adriaens E, Almeida A, Quinten T, De Vos F . In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC. Ann Surg Oncol. 2010; 17(9):2510-7. DOI: 10.1245/s10434-010-1028-x. View

12.

Pelz J, Vetterlein M, Grimmig T, Kerscher A, Moll E, Lazariotou M . Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol. 2013; 20(4):1105-13. DOI: 10.1245/s10434-012-2784-6. View

13.

Aarts F, Bleichrodt R, Man B, Lomme R, Boerman O, Hendriks T . The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol. 2008; 15(11):3299-307. DOI: 10.1245/s10434-008-0070-4. View

14.

Jacquet P, AVERBACH A, Stuart O, Chang D, Sugarbaker P . Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998; 41(2):147-54. DOI: 10.1007/s002800050721. View

15.

Bespalov V, Kireeva G, Belyaeva O, Kalinin O, Senchik K, Stukov A . Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model. J Surg Oncol. 2015; 113(4):438-42. DOI: 10.1002/jso.24140. View

16.

Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S . Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1):34-43. DOI: 10.1056/NEJMoa052985. View

17.

Struller F, Horvath P, Solass W, Weinreich F, Strumberg D, Kokkalis M . Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019; 11:1758835919846402. PMC: 6535725. DOI: 10.1177/1758835919846402. View

18.

Facy O, Radais F, Ladoire S, Delroeux D, Tixier H, Ghiringhelli F . Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis. J Exp Clin Cancer Res. 2011; 30:4. PMC: 3024948. DOI: 10.1186/1756-9966-30-4. View

19.

Azais H, Queniat G, Bonner C, Kerdraon O, Tardivel M, Jetpisbayeva G . Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy. Int J Gynecol Cancer. 2015; 25(7):1194-200. DOI: 10.1097/IGC.0000000000000497. View

20.

Pelz J, Doerfer J, Dimmler A, Hohenberger W, Meyer T . Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006; 6:162. PMC: 1552087. DOI: 10.1186/1471-2407-6-162. View